Customization of biliopancreatic limb length to modulate and sustain antidiabetic effect of gastric bypass surgery.

ABSTRACT: Although Roux-en-Y Gastric Bypass (RYGB) remains the most effective treatment for obesity and type 2 diabetes (T2D), many patients fail to achieve remission, or relapse. Increasing intestinal limb lengths of RYGB may improve outcomes, but the mechanistic basis for this remains unclear. We hypothesize biliopancreatic (BP) limb length modulates the antidiabetic effect of RYGB. Rats underwent RYGB with a 20-cm (RYGB-20cm) or 40-cm (RYGB-40cm) BP limb and were compared with control animals. After 2 and 4 wk, portal and systemic blood was sampled during intestinal glucose infusion. Portosystemic gradient was used to calculate intestinal glucose utilization (G_util), absorption (G_absorp), and hormone secretion. Intestinal morphology and gene expression were assessed. At 2 wk

SUBMITTER: Pal A 

PROVIDER: S-EPMC5866424 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature